Selinexor is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Tianjin Medical University Cancer Institute and Hospital, with a possible patent signal linked through modality_match. Manual review is still required.
Target: Unknown
Cell type: NK_CELL
Indications: Extensive Stage Lung Small Cell Cancer
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Institution: Tianjin Medical University Cancer Institute and Hospital
Phase: Phase2
Status: Not Yet Recruiting
Trial count: 1
Active trials: 0
First posted: September 15, 2025
Last updated: September 30, 2025
IP signal: Possible
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT07172412